glp 1 drugs menopause GLP-1s and Hormone Therapy: A Game-Changing Duo for Belly Fat GLP-1 for Menopause Weight Loss

Efficacy and safety of once-weekly efpeglenatide monotherapy versus placebo in type 2 diabetes: the AMPLITUDE-M randomized controlled trial

Future Outlook The obesity therapeutics market is poised to evolve into a multi-dimensional ecosystem combining pharmacology, technology, and behavioral science

In diabetes care, GLP-1 receptor agonists are widely integrated into treatment guidelines and reimbursement systems

Hippo signaling, actin polymerization, and follicle activation in fragmented human ovarian cortex

Appetite rebounds, often exceeding pre-treatment levels in the short term

The wellness industry commonly uses sly marketing to sell products of dubious effectiveness, but theres something especially unnerving about its attempt to move into the obesity-drug space